The Center for the Neurobiology of Addiction Treatment (CNAT) is a renewal of a P50 Center at Wake Forest University Health Sciences that has been continuously funded by NIDA since 1991 and extensively re- designed at its last funding in 2009.
The Specific Aims are: 1. to provide a novel mechanism of interaction among NIDA investigators at Wake Forest University to examine neurobiological mechanisms of cocaine pharmacotherapies, using tightly interacting projects to ensure an effective collaborative structure; 2. to provide a formal structure of collaborative interactions between our Center and our clinical partners at NIDA-funded clinical centers, thus providing a novel translational component to our research; 3. to provide a focus for the training of students and postdoctoral fellows in contemporary methods for investigating the neurobiological basis of drug abuse; 4. to serve as an information source to both the lay and scientific community on issues related to the neurobiological aspects of drug abuse. The scientific theme of the Center is focused on examining the neurobiological mechanisms of action of potential cocaine pharmacotherapeutic agents, with a focus on the use of drug combinations, using two treatment drugs that act through different pharmacological mechanisms to provide synergistic effects. The Center's novel strategy to identify potential drug combination pharmacotherapies is to utilize one drug that decreases cocaine reinforcement through the nucleus acumens dopaminergic pathway, with the other drug acting to reverse cocaine-induced deficits in cognition, i.e., cognitive remediators. The Center contains three cores and three major projects. The projects are highly interactive, with each project's activities dependent on results obtained from the other two projects. Project 1 will examine effects of combination drug treatment on various behavioral models in both rats and monkeys; Project 2 will explore how these combination drug treatment paradigms affect functional consequences in brain through neuro-imaging and voltammetry; and Project 3 will explore how these drug treatments affect gene expression, receptor function and signal transduction systems. The Center contains an Administrative Core and a Pilot Studies Core, while the Animal/Tissue Core will provide uniform sets of brain tissue samples from different rat models to the projects. These projects utilize several animal behavioral models and technologies uniquely developed by the Center investigators over the previous years of its funding history.

Public Health Relevance

Cocaine is a highly addictive and dangerous drug of abuse. This Center uses a variety of experienced researchers and laboratories to study potential medications to treat cocaine addiction, and serves as a national resource for the development of cocaine treatment agents.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA006634-25
Application #
9232099
Study Section
Special Emphasis Panel (ZDA1-NXR-B (04)S)
Program Officer
Volman, Susan
Project Start
1991-09-30
Project End
2020-02-29
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
25
Fiscal Year
2017
Total Cost
$1,428,114
Indirect Cost
$494,346
Name
Wake Forest University Health Sciences
Department
Physiology
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Siciliano, Cody A; Saha, Kaustuv; Calipari, Erin S et al. (2018) Amphetamine Reverses Escalated Cocaine Intake via Restoration of Dopamine Transporter Conformation. J Neurosci 38:484-497
Ilyasov, Alexander A; Milligan, Carolanne E; Pharr, Emily P et al. (2018) The Endocannabinoid System and Oligodendrocytes in Health and Disease. Front Neurosci 12:733
Ding, Huiping; Kiguchi, Norikazu; Yasuda, Dennis et al. (2018) A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Sci Transl Med 10:
Chen, R; McIntosh, S; Hemby, S E et al. (2018) High and low doses of cocaine intake are differentially regulated by dopamine D2 receptors in the ventral tegmental area and the nucleus accumbens. Neurosci Lett 671:133-139
John, William S; Martin, Thomas J; Solingapuram Sai, Kiran Kumar et al. (2018) Chronic ?9-THC in Rhesus Monkeys: Effects on Cognitive Performance and Dopamine D2/D3 Receptor Availability. J Pharmacol Exp Ther 364:300-310
Siciliano, Cody A; McIntosh, J Michael; Jones, Sara R et al. (2017) ?6?2 subunit containing nicotinic acetylcholine receptors exert opposing actions on rapid dopamine signaling in the nucleus accumbens of rats with high-versus low-response to novelty. Neuropharmacology 126:281-291
Shaw, Jessica K; Ferris, Mark J; Locke, Jason L et al. (2017) Hypocretin/orexin knock-out mice display disrupted behavioral and dopamine responses to cocaine. Addict Biol 22:1695-1705
Siciliano, Cody A; Jones, Sara R (2017) Cocaine Potency at the Dopamine Transporter Tracks Discrete Motivational States During Cocaine Self-Administration. Neuropsychopharmacology 42:1893-1904
Brodnik, Zachary D; Ferris, Mark J; Jones, Sara R et al. (2017) Reinforcing Doses of Intravenous Cocaine Produce Only Modest Dopamine Uptake Inhibition. ACS Chem Neurosci 8:281-289
Fordahl, Steve C; Jones, Sara R (2017) High-Fat-Diet-Induced Deficits in Dopamine Terminal Function Are Reversed by Restoring Insulin Signaling. ACS Chem Neurosci 8:290-299

Showing the most recent 10 out of 310 publications